Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

V 212

Drug Profile

V 212

Alternative Names: Inactivated varicella-zoster vaccine - Merck; V212; Varicella zoster virus vaccine - Merck; VZV vaccine - Merck

Latest Information Update: 04 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Merck & Co
  • Class Varicella vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Herpes zoster

Most Recent Events

  • 11 Apr 2017 Merck completes a phase III trial for Herpes zoster (Prevention) in the US, Argentina, Colombia, Ecuador, Puerto Rico, Belgium, Bulgaria, Estonia, India, South Korea, Spain, Germany, Czech Republic, UK, Austria, Slovakia, Lithuania, Greece and Italy (NCT01254630)
  • 24 Feb 2017 Efficacy and adverse events data from a phase III trial in Herpes zoster released by Merck and Co
  • 29 May 2015 No recent reports on development identified - Phase-II for Herpes zoster (Prevention) in Australia, Canada, Denmark and Israel (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top